This study aims to realize an economic evaluation of the introduction of Plerixafor in addition to G-CSF and alternative options, in patients with multiple myeloma (MM) who failed or insufficiently mobilize peripheral blood stem and progenitor cells in response to G-CSF alone.
No linked publications found in PubMed
Inclusion Criteria: * Adult patients diagnosed with Multiple Myeloma who were eligible for high-dose melphalan supported with autologous hematopoietic stem cell transplantation (HSCT) as part of their treatment plan * First mobilization attempt * "rhG-CSF alone" mobilization regimen * Failed mobilization as documented by an increase in CD34+ cell mobilization deemed insufficient to initiate apheresis (below 15/µL), after the 4 first injections of rhG-CSF that are administered in the evening Exclusion Criteria: * Age \< 18 years; * Primary diagnosis other than MM * 2nd or subsequent mobilization attempt * Patients who previously received HDCT + autologous HSCT * Chemotherapy-based mobilization regimen * Efficient mobilization, allowing for apheresis and collection of the target cell number (5x106 CD34+ cells/kg for every planned autologous transplantation as per institutional SOPs).